2020
Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis
Jiang R, Hoehn KB, Lee CS, Pham MC, Homer RJ, Detterbeck FC, Aban I, Jacobson L, Vincent A, Nowak RJ, Kaminski HJ, Kleinstein SH, O'Connor KC. Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2020, 117: 30649-30660. PMID: 33199596, PMCID: PMC7720237, DOI: 10.1073/pnas.2007206117.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAutoantibodiesBiomarkersB-LymphocytesClonal EvolutionClonal Selection, Antigen-MediatedDisease SusceptibilityFemaleHumansLymphocyte CountMaleMiddle AgedModels, BiologicalMyasthenia GravisRadioimmunoassayReceptors, CholinergicThymectomyThymus GlandV(D)J RecombinationYoung AdultConceptsB cell clonesMyasthenia gravisB cell repertoireB cellsCell clonesPlasma cellsCell repertoireAdditional immunosuppressive treatmentDiminished clinical responseThymic lymphofollicular hyperplasiaComplete stable remissionMajority of patientsAntigen-experienced B cellsRandomized clinical trialsClinical symptom measuresAChR autoantibodiesImmunosuppressive treatmentSteroid doseAutoantibody titersMG thymusClinical responseStable remissionClinical scoresAutoimmune diseasesClinical trials
2013
Screening for Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Detterbeck FC, Mazzone PJ, Naidich DP, Bach PB. Screening for Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST Journal 2013, 143: e78s-e92s. PMID: 23649455, PMCID: PMC3749713, DOI: 10.1378/chest.12-2350.Peer-Reviewed Original ResearchConceptsLung cancer deathsLung cancerCancer deathChest Physicians Evidence-Based Clinical Practice GuidelinesEvidence-based clinical practice guidelinesLow-dose CT screeningMajority of patientsRisk of complicationsClinical practice guidelinesLung cancer diagnosisSignificant reductionNumber of deathsLDCT screeningCurative treatmentLarge RCTsCT screeningTreatment recommendationsChest radiographsPractice guidelinesAmerican CollegeEffective treatmentElevated riskResult of screeningAdvanced stageSystematic review
2012
Stereotactic Body Radiotherapy for Central Lung Tumors
Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Stereotactic Body Radiotherapy for Central Lung Tumors. Journal Of Thoracic Oncology 2012, 7: 1394-1399. PMID: 22843088, DOI: 10.1097/jto.0b013e3182614bf3.Peer-Reviewed Original ResearchConceptsStereotactic body radiotherapyCentral lung tumorsBiological equivalent doseLocal recurrenceTracheobronchial treeLung tumorsBody radiotherapyCentral lesionsEquivalent doseGrade 3Baseline pulmonary function testsLarger maximum tumor diameterMedian biological equivalent doseChest wall painGrade 3 dyspneaYale Cancer CenterGrade 2 toxicityLocal control ratePrimary lung cancerPulmonary function testsHigh-grade toxicityMajority of patientsVolume of lungMaximum tumor diameterMaximum point dose
2008
The Feasibility of Adjuvant Carboplatin and Docetaxel in Patients with Curatively Resected Non-small Cell Lung Cancer
Stinchcombe TE, Harper HD, Hensing TA, Moore DT, Crane JM, Atkins JN, Willard EM, Detterbeck FC, Socinski MA. The Feasibility of Adjuvant Carboplatin and Docetaxel in Patients with Curatively Resected Non-small Cell Lung Cancer. Journal Of Thoracic Oncology 2008, 3: 145-151. PMID: 18303435, DOI: 10.1097/jto.0b013e318160c5f1.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantDocetaxelDrug-Related Side Effects and Adverse ReactionsFeasibility StudiesFemaleHumansLung NeoplasmsMaleMiddle AgedPatient ComplianceSurvival AnalysisTaxoidsConceptsNon-small cell lung cancerCell lung cancerAdjuvant therapySupportive therapyChemotherapy complianceLung cancerAdequate exposureResected non-small cell lung cancerAdjuvant cisplatin-based chemotherapyMulticenter phase II trialMedian age 65 yearsCycles of therapyPrimary end pointAcceptable toxicity profileBetter functional statusPhase II trialCisplatin-based chemotherapyMajority of patientsSquamous cell carcinomaAge 65 yearsAdjuvant carboplatinCommon histologyII trialIntercurrent illnessActive therapy
2003
Gemcitabine-Based Combinations as Preoperative Therapy in Resectable Non–Small-Cell Lung Cancer
Socinski MA, Rivera MP, Detterbeck FC. Gemcitabine-Based Combinations as Preoperative Therapy in Resectable Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2003, 4: s50-s55. PMID: 14720337, DOI: 10.3816/clc.2003.s.004.Peer-Reviewed Original ResearchGemcitabine-containing regimensPhase III trialsStage III NSCLCComplete surgical resectionPreoperative therapyIII trialsSurgical resectionInduction therapyLung cancerResectable non-small cell lung cancerNon-small cell lung cancerDominant recurrence patternGemcitabine-based combinationsSystemic micrometastatic diseaseCisplatin/gemcitabinePhase II trialMajority of patientsMinority of patientsCell lung cancerOverall response rateStandard of careAdjuvant chemotherapyAdvanced NSCLCII trialStage IB